Large Cell Neuroendocrine Cancer (LCNEC) clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
open to eligible people ages 18 years and up
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
at UCSF
Our lead scientists for Large Cell Neuroendocrine Cancer (LCNEC) research studies include Rahul Aggarwal.
Last updated: